Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study.
Sato S, Uehara T, Toyoda K, Yasui N, Hata T, Ueda T, Okada Y, Toyota A, Hasegawa Y, Naritomi H, Minematsu K; Stroke Unit Multicenter Observational (SUMO) Study Group. Sato S, et al. Stroke. 2009 Jan;40(1):30-4. doi: 10.1161/STROKEAHA.108.524942. Epub 2008 Oct 23. Stroke. 2009. PMID: 18948604
Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register.
Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Nishiyama K, Minematsu K; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Toyoda K, et al. Among authors: yamagami h. Stroke. 2009 Nov;40(11):3591-5. doi: 10.1161/STROKEAHA.109.562991. Epub 2009 Sep 17. Stroke. 2009. PMID: 19762694
Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS).
Yamagami H, Sakai N, Matsumaru Y, Sakai C, Kai Y, Sugiu K, Fujinaka T, Matsumoto Y, Miyachi S, Yoshimura S, Hyogo T, Kuwayama N, Hyodo A. Yamagami H, et al. J Stroke Cerebrovasc Dis. 2012 Apr;21(3):193-9. doi: 10.1016/j.jstrokecerebrovasdis.2010.06.007. Epub 2010 Sep 19. J Stroke Cerebrovasc Dis. 2012. PMID: 20851621
Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy: stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry.
Nezu T, Koga M, Nakagawara J, Shiokawa Y, Yamagami H, Furui E, Kimura K, Hasegawa Y, Okada Y, Okuda S, Kario K, Naganuma M, Maeda K, Minematsu K, Toyoda K. Nezu T, et al. Among authors: yamagami h. Stroke. 2011 Aug;42(8):2196-200. doi: 10.1161/STROKEAHA.111.614404. Epub 2011 Jun 30. Stroke. 2011. PMID: 21719764
Low-dose intravenous recombinant tissue-type plasminogen activator therapy for patients with stroke outside European indications: Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rtPA Registry.
Koga M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Endo K, Miyagi T, Osaki M, Minematsu K, Toyoda K. Koga M, et al. Among authors: yamagami h. Stroke. 2012 Jan;43(1):253-5. doi: 10.1161/STROKEAHA.111.631176. Epub 2011 Sep 29. Stroke. 2012. PMID: 21960585
Stroke outcomes of Japanese patients with major cerebral artery occlusion in the post-alteplase, pre-MERCI era.
Endo K, Koga M, Sakai N, Yamagami H, Furui E, Matsumoto Y, Shiokawa Y, Yoshimura S, Okada Y, Nakagawara J, Hyogo T, Hasegawa Y, Nagashima H, Fujinaka T, Hyodo A, Terada T, Toyoda K; Joint Research Group from JR-NET2 and SAMURAI Study Investigators. Endo K, et al. Among authors: yamagami h. J Stroke Cerebrovasc Dis. 2013 Aug;22(6):805-10. doi: 10.1016/j.jstrokecerebrovasdis.2012.05.009. Epub 2012 Jun 19. J Stroke Cerebrovasc Dis. 2013. PMID: 22721823
605 results